Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AT7519||AT7519M||CDK1 Inhibitor 13 CDK2 Inhibitor 19 CDK4 Inhibitor 12 CDK4/6 Inhibitor 9 CDK5 Inhibitor 7 CDK6 Inhibitor 3 CDK9 Inhibitor 16||AT7519 is an ATP competitive inhibitor of CDK1, CDK2, CDK4, CDK5, CDK6, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 19174555).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||AT7519||Phase I||Actionable||In a Phase I trial, AT7519 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 25393368).||25393368|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02503709||Phase I||AT7519 Onalespib||Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery||Active, not recruiting|